OTCMKTS:BNXTF BioNxt Solutions (BNXTF) Stock Price, News & Analysis → The World's First '$20 Trillion Drug?' (From Behind the Markets) (Ad) Free BNXTF Stock Alerts $0.30 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.30▼$0.3050-Day Range$0.30▼$0.5052-Week Range$0.00▼$0.57VolumeN/AAverage Volume841 shsMarket Capitalization$32.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest Get BioNxt Solutions alerts: Email Address Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About BioNxt Solutions Stock (OTCMKTS:BNXTF)BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, the United States, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.Read More BNXTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNXTF Stock News HeadlinesApril 26, 2024 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Solutions Announces ODF Cladribine Update and FinancingMarch 18, 2024 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Reports Commercialization of ODF Cladribine Product for MS Next StepsApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 13, 2024 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Reports Successful Results From ODF Cladribine PK StudyMarch 4, 2024 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Reports Completion of ODF Cladribine PK StudyFebruary 19, 2024 | msn.comBioNxt Solutions finalizes debt settlement agreementFebruary 16, 2024 | finance.yahoo.comBioNxt Solutions Finalizes AgreementFebruary 7, 2024 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Reports Successful Results From ODF Cladribine Toxicity StudyApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…February 7, 2024 | finance.yahoo.comBioNxt Reports Successful Results From ODF Cladribine Toxicity StudyJanuary 30, 2024 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Solutions Announces Closing of Final Tranche of Non-Brokered Private PlacementJanuary 30, 2024 | finance.yahoo.comBioNxt Solutions Announces Closing of Final Tranche of Non-Brokered Private PlacementJanuary 5, 2024 | ca.finance.yahoo.comBioNxt Solutions Inc. (BNXT.CN)December 23, 2023 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and FinancingDecember 21, 2023 | finance.yahoo.comBioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and FinancingDecember 12, 2023 | finance.yahoo.comBioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery ProductsDecember 9, 2023 | finance.yahoo.comBioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder’s WarrantsNovember 24, 2023 | benzinga.comBionxt Solutions Announces Convertible Debenture and Interest SettlementNovember 20, 2023 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis TreamentNovember 20, 2023 | finance.yahoo.comBioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis TreamentNovember 16, 2023 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Reports on New Cladrabine ODF Product Development and Commercialization ProgramNovember 15, 2023 | finance.yahoo.comBioNxt Reports on New Cladrabine ODF Product Development and Commercialization ProgramNovember 13, 2023 | finance.yahoo.comBioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple SclerosisNovember 6, 2023 | benzinga.comBioNxt Solutions berichtet über CPHI-Kongress in BarcelonaNovember 6, 2023 | finance.yahoo.comBioNxt Solutions Reports on Barcelona CPHI ConferenceOctober 27, 2023 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private PlacementOctober 27, 2023 | finance.yahoo.comBioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private PlacementSee More Headlines Receive BNXTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNxt Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:BNXTF CUSIPN/A CIKN/A Webwww.xphyto.com Phone780-818-6422FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,520,000.00 Net Margins-2,508.06% Pretax Margin-2,660.48% Return on EquityN/A Return on Assets-317.48% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.28 Sales & Book Value Annual Sales$280,000.00 Price / Sales117.07 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-10.00Miscellaneous Outstanding Shares109,269,000Free FloatN/AMarket Cap$32.78 million OptionableNot Optionable Beta0.89 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Hugh A. D. Rogers B.Sc. (Age 44)LL.B, President, CEO & Director Comp: $175kMr. Patrick Joseph Meagher C.A. (Age 38)CPA, CA, CPA, CFO & Director Comp: $52.4kDr. Florian A. SahrHead of Project ManagementKey CompetitorsIN8bioNASDAQ:INABNutex HealthNASDAQ:NUTXViracta TherapeuticsNASDAQ:VIRXPrecision OpticsNASDAQ:POCIPrecision OpticsOTCMKTS:PEYEView All Competitors BNXTF Stock Analysis - Frequently Asked Questions How have BNXTF shares performed in 2024? BioNxt Solutions' stock was trading at $0.3809 on January 1st, 2024. Since then, BNXTF stock has decreased by 21.2% and is now trading at $0.30. View the best growth stocks for 2024 here. How do I buy shares of BioNxt Solutions? Shares of BNXTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BNXTF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNxt Solutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.